Recently, the gastrointestinal microbiome, and its metabolites, has emerged as a potential regulator of host metabolism. However, to date little is known on the precise mechanisms of how this regulation occurs. Hydrogen sulfide (H 2 S) is abundantly produced in the colon by sulfate-reducing bacteria (SRB). H 2 S is a bioactive gas that plays regulatory roles in many systems, including metabolic hormone regulation. This gas metabolite is produced in close proximity to the glucagonlike peptide-1 (GLP-1)-secreting cells in the gut epithelium. GLP-1 is a peptide hormone that plays pivotal roles in both glucose homeostasis and appetite regulation. We hypothesized that H 2 S can directly regulate GLP-1 secretion. We demonstrated that H 2 S donors (NaHS and GYY4137) directly stimulate GLP-1 secretion in murine L-cells (GLUTag) and that this occurs through p38 mitogen-activated protein kinase without affecting cell viability. We then increased SRB in mice by supplementing the diet with a prebiotic chondroitin sulfate for 4 weeks. Mice treated with chondroitin sulfate had elevated Desulfovibrio piger levels in the feces and increased colonic and fecal H 2 S concentration. These animals also had enhanced GLP-1 and insulin secretion, improved oral glucose tolerance, and reduced food consumption. These results indicate that H 2 S plays a stimulatory role in GLP-1 secretion and that sulfate prebiotics can enhance GLP-1 release and its downstream metabolic actions. (Endocrinology 158: 3416-3425, 2017) 
O besity and its associated metabolic comorbidities, including cardiovascular disease, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease, and others (1), continue to affect a growing proportion of the world's population. A recently approved treatment in both T2DM and obesity are incretin-based therapies. These gastrointestinal (GI) hormones, including glucagonlike peptide-1 (GLP-1), are released from enteroendocrine cells in the GI tract and regulate many of our metabolic functions such as appetite, glucose homeostasis, and gastric motility (2) (3) (4) (5) . Due to its appetite-suppressing and insulinotropic actions of GLP-1, GLP-1-based therapies are now an attractive noninsulinic option for patients with T2DM (6) (7) (8) or morbid obesity (7, 9) .
In the last decade, the GI microbiome has emerged as a potential regulator of overall metabolism. Metabolic disorders such as obesity and T2DM have been closely linked with changes in gut microbiota (10) (11) (12) . Indeed, the gut microbiome has the ability, when transplanted, to alter energy homeostasis and weight gain (13) . Importantly, interactions between the gut microflora and the enteroendocrine system have been recently demonstrated. Short-chain fatty acids, end products of intestinal bacterial fermentation, significantly increase the release of postprandial plasma GLP-1 in humans and mice (14, 15) . Indole, an end product of bacterial tryptophan breakdown, stimulates GLP-1 secretion in acute treatments in vitro (16) . Many other bacterial metabolites are present in the gut from colonic microbial metabolism, including polyphenols, secondary bile acids, and sulfur compounds (17) ; however, relatively little is known of the interaction of these bacterial metabolites and the local enteroendocrine cells of the GI tract.
Hydrogen sulfide (H 2 S) is a bacterial metabolite that is produced by sulfate-reducing bacteria (SRB) in the colon and endogenously in many mammalian cell types. The endogenous production of H 2 S (in nanomolar amounts) is known as an essential signal transmitting molecule, termed "gasotransmitter," that acts on a variety of systems, including cardiovascular, nervous, muscular, and endocrine (18) (19) (20) . Of key importance, millimolar concentrations of microbial H 2 S can be found within the lumen of the colon (19, 21, 22) . This environment also contains the highest proportion of GLP-1-secreting L-cells (23) . Despite this proximity, and the known role of H 2 S as an endocrine modulator, very little is understood regarding the potential crosstalk between the H 2 S and GLP-1. The goal of this study was to investigate the role of H 2 S in the regulation of GLP-1. In vitro, this was done directly by using H 2 S donors on the murine GLP-1-secreting GLUTag cell line. In vivo, a previously validated SRB prebiotic diet containing chondroitin sulfate was used to increase SRB and H 2 S production. GLP-1 secretion, food consumption, and glucose tolerance were then examined in mice with enhanced SRB and H 2 S levels.
Materials and Methods

Animals
Experiments were performed following the guidelines outlined by the Canadian Council on Animal Care guide to the Care and Use of Experimental Animals (24, 25) . Animal protocols were approved by the Laurentian University Animal Care Committee. Male wild-type C57BL/6 mice aged 5 to 6 weeks were purchased from Charles River Laboratories (St. Constant, QC, Canada) and singly housed in standard cages on a 12-hour light/dark cycle in the Paul Field Animal Care Facility at Laurentian University.
Diet and study design
After a week-long acclimatization period on chow diet, 26 male mice were randomly divided into two groups. Animals were fed a diet ad libitum low in fermentable carbohydrate [20% weight/weight (wt/wt) fat and 47% wt/wt sucrose] with or without chondroitin sulfate (3% wt/wt) for 4 weeks (custom diet prepared by Envigo Teklad Diets, Madison, WI) as previously done (26) . Animals had access to water ad libitum. Body weight and food intake were recorded daily, and fecal material was collected and frozen every 2 days. Blood was collected every 2 weeks after an oral glucose gavage for glucose and or GLP-1 measurements.
Oral glucose tolerance test
An oral glucose tolerance test (OGTT) was performed at 0, 2, and 4 weeks of the study. After being held without food overnight, mice received an oral gavage of D-(+)-glucose (2 g/kg body wt). A small incision was made at the distal end of the lateral tail vein, and blood was collected into EDTA-coated capillary tubes for GLP-1 measurements at 0, 10, and 60 minutes after glucose gavage (27) . An aprotinin (protease inhibitor), diprotin A (DPP-4 inhibitor), and additional EDTA cocktail were supplemented to the capillary tubes (10% v/v) to prevent degradation of the target hormone. Blood glucose was measured during the experiment using a glucometer (OneTouch Verio) at 0, 10, 60, and 90 minutes after glucose administration.
GLP-1 analysis
Blood samples were collected on ice from the OGTT experiment from the lateral tail vein of the mouse. Whole blood (60 mL) was centrifuged for 10 minutes at 6000 g at 4°C. Plasma (25 mL) was examined for total GLP-1 using a commercial competitive ELISA kit (Sigma-Aldrich, St. Louis, MO).
Fecal microbe genomic analysis
Fecal material was collected from the mice by grasping the skin around the neck and positioning the mouse upright until a fecal pellet was excreted directly into the DNA extraction tube or by placing the animal in a clean cage and collecting the fecal sample with sterile forceps. Approximately two to five stool pellets were collected per mouse per collection period (;40 to 100 mg). After collection, samples were stored at 280°C until analysis. Genomic DNA was extracted from equal fecal weight (30 mg) samples using FavorPrepStool DNA Isolation Mini Kit as directed by the manufacturer (Favorogen Biotech Corp.), and the DNA samples were eluted in 50-mL aliquots. The concentration and purity of the resulting DNA was determined by 260 and 280 nm spectrophotometry and stored at 220°C. 0 -ACGTCRTCCMCACCTTCCTC-3 0 . Quantitative real-time polymerase chain reactions (PCRs) (10 mL) contained 2 mL of 10x diluted template DNA, 5 mL 2X SensiFast SYBR No-ROX supermix (Bioline Inc., Taunton, MA), 0.5 mL of forward and reverse primers, and 2.5 mL sterile H 2 O. As directed by the manufacturer, PCR was comprised of an initial denaturation step of 95°C for 1 minute, followed by 40 cycles of 95°C for 15 seconds, 55°C for 15 seconds, and 72°C for 15 seconds. Standards and samples were run in triplicate, and cycle threshold values were averaged. Quantification was completed using the standard curve method, with D. piger being normalized to total bacterial (ribosomal 16s).
Targeted real-time polymerase chain reaction
H 2 S measurement
Fecal and colonic content H 2 S levels were quantified using the methylene blue method (29) . Colonic contents were collected after animals were euthanized. Material (;0.1g) was homogenized with 1% zinc acetate trapping solution, 20 mM N,N-dimethyl-p-phenylenediamine sulfate in 7.2 N HCl, and 30 mM FeCL3 in 1.2 N HCl and incubated for 30 minutes. Samples were centrifuged, and the clear upper phase was analyzed at 670 nm in comparison with a calibration curve of standard H 2 S solutions (30, 31) . H 2 S levels were expressed in mM/g wet weight.
Cell culture and GLP-1 secretion
Mouse GLP-1-secreting GLUTag cells (passage 10 to 30; a kind contribution from Dr. Drucker, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada) were grown as previously described by Gil-Lozano and Brubaker (32) .
GLUTag cells were seeded in 6-well plates (1,000,000 cells per well) and received treatment upon reaching approximately 80% confluence after 48 hours. Cells were treated for 2 hours (33) with H 2 S donors: sodium hydrosulfide (NaHS) (Fisher Scientific, Mississauga, ON, Canada) or GYY4137 (Cayman Chemicals, Ann Armor, MI) dissolved in low-serum Dulbecco's modified Eagle medium (0.5% fetal bovine serum) (GE Health Care Life Sciences, Missussauga, ON, Canada). Media with vehicle served as a control for baseline secretion, and forskolin was used as a positive control for GLP-1 secretion (data not shown). For p38 mitogen-activated protein kinase (MAPK) inhibition, the inhibitor 2,2 0 -sulfonyl-bis-(3,4,6-trichlorophenol) (p38 MAPK inhibitor IV) was coincubated with treatments (Sigma-Aldrich, Oakville, ON, Canada). Total cellular protein content was assayed using the Bradford method, and no differences were observed (data not shown). After the incubation, the collected media was acidified using trifluoroacetic acid to a final concentration of 0.1% and purified through a Sep-Pak C18 as per the manufacturers' instructions (Waters Canada, Mississauga, ON, Canada). The retained material was eluted with 80% isopropanol and 0.1% trifluoroacetic acid and then dried using the Integrated Speedvac System. The dried purified samples were stored at 220°C until analysis. A commercial total GLP-1 competitive ELISA kit (Sigma-Aldrich, St. Louis, MO) was used to quantify GLP-1 levels from dried samples. Under similar experimental conditions, cell viability was determined by neutral red uptake assay as described previously (34) .
Western blot
GLUTag cells were seeded into 6-well plates for 48 hours. Cells were treated for 10 minutes in serum-free media containing vehicle or an H 2 S donor. Cells were lysed in lysis buffer (Cell Signaling Technologies, Danvers, MA) containing phosphatase inhibitor (PhosphoSTOP; Roche Diagnostics, Laval, PQ, Canada) and protease inhibitor (EDTA Free CompleteMini; Roche). Protein content was quantified by Bradford method, separated on an 8% denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis Tris-glycine gel, transferred to a polyvinylidene fluoride membrane, blocked with 5% skim milk in Tris-buffered saline, and incubated overnight at 4°C with primary antibodies. After washing in Tris-buffered saline, the membrane was incubated for 2 hours at room temperature with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Cell Signaling Technologies, Danvers, MA). The proteins were visualized using a Luminata Forte chemiluminescence horseradish peroxidase substrate (Millipore Corp., Billerica, MA), and luminescence was detected using the BioRad chemi doc XRS system (for antibodies, see Table 1 ).
Statistical analysis
All data are expressed as mean 6 standard error of the mean. Studies comparing two groups were analyzed by Student t test. Studies with multiple doses of the same treatment were analyzed by one-way analysis of variance (ANOVA), followed by a Bonferroni post hoc test. Studies with two or more independent variables (i.e., time and treatment doses) were analyzed by twoway ANOVA, followed by Bonferroni post hoc tests at individual time points where applicable. P , 0.05 was considered significant.
Results
H 2 S donors stimulate GLP-1 secretion in vitro
To determine the direct effect of H 2 S on GLP-1 secretion, GLUTag cells were treated with an H 2 S donor (NaHS or GYY4137) or with vehicle media for 2 hours. Sodium hydrosulfide (NaHS) increased GLP-1 secretion (P , 0.05; one-way ANOVA), with the highest dose of NaHS (10 mM) causing a 1.98 6 0.2-fold increase (Fig. 1A) . GYY4137 also caused a significant increase of GLP-1 levels (P , 0.05; one-way ANOVA), with the highest dose of GYY4137 (100 mM) producing a 2.2 6 0.21-fold increase of GLP-1 (Fig. 1B) . All H 2 S donors used did not reduce cell viability, as shown by the neutral red assay (Fig. 1C) .
p38 MAPK is involved in H 2 S-stimulated GLP-1 secretion in vitro
To determine potential intracellular mechanisms involved in the enhanced GLP-1 secretion by H 2 S, we treated GLUTag cells with the most effective dose of NaHS (10 mM) for 10 minutes and examined the phosphorylation of p38 MAPK and AKT by Western blot. No change in AKT phosphorylation was observed (Fig. 1A) . p38 MAPK phosphorylation was significantly increased by 1.61 6 0.18-fold after treatment (P , 0.05) (Fig. 2B) . To confirm the importance of p38 MAPK in H 2 S-stimulated GLP-1 secretion, we coincubated the p38 MAPK inhibitor IV with NaHS. NaHS-stimulated GLP-1 secretion was completely blocked by the addition of the 50 nM p38 MAPK kinase IV inhibitor (Fig. 2C) . No secretion inhibition was observed at higher doses of the inhibitor (100 to 1000 nM; data not shown). 
Chondroitin sulfate prebiotic diet increases H 2 S and SRB levels
To increase the amount of SRB and microbial H 2 S in vivo, mice were provided with a prebiotic diet consisting of a 3% chondroitin sulfate in the presence of a diet low in fermentable carbohydrate. Fecal DNA was collected throughout the study and analyzed for the abundance of D. piger using targeted quantitative PCR. In comparison with the respective baseline levels, both groups had an increase in D. piger levels (Fig. 3A) . Importantly, there was a 1.29 6 0.07-fold increase in treatment vs control D. piger levels after the 4-week diet (P , 0.05 for chondroitin sulfate interaction in two-way ANOVA) (Fig. 3A) . Therefore, the prebiotic chondroitin sulfate significantly increased the abundance of D. piger.
To verify that this increased fecal D. piger level corresponded with increased levels of H 2 S, the amounts of fecal and terminal colon H 2 S were determined using the methylene blue method. The prediet intervention levels (in feces) were similar in both control and treatment groups (0.49 mmol/g) (Fig. 3B) . However, after the 4-week prebiotic diet, fecal H 2 S levels were significantly elevated in the chondroitin sulfate group (P , 0.05 for chondroitin sulfate for interaction and prebiotic) (Fig. 3B) . Because colonic content is less exposed to oxygen (a factor that causes loss of H 2 S), terminal H 2 S was examined from colonic material. The prebiotic treatment group had a 1.50 6 0.03-fold increase of colonic content H 2 S (0.81 mmol/g) compared with control (P , 0.05) (Fig. 3C) .
Chondroitin sulfate prebiotic diet improves oral glucose clearance, enhances GLP-1 response, and reduces feeding
To determine if the chondroitin sulfate-induced increase in SRB and H 2 S coincided with incretin and metabolic changes, glucose tolerance, GLP-1 secretion, insulin secretion, and food consumption were examined. Oral glucose tolerance was similar at days 0 and 14 ( Fig. 4Ai and 4Aii) . At day 28, the chondroitin sulfate group had significantly improved glucose tolerance (overall treatment effect compared with control, P , 0.01; with post hoc significance at 60 minutes, P , 0.01) ( Fig. 4Aiii) . Area under the curve (AUC) of day 28 glucose was also significantly lower in the prebiotic group (0.87 6 0.05 of control; P , 0.05) (Fig. 4B) . At day 28, mice treated with chondroitin sulfate had a significant increase in glucose-stimulated GLP secretion (overall treatment effect compared with control, P , 0.05; with post hoc significance at 10 minutes, P , 0.001) (Fig. 4C) . AUC for GLP-1 secretion was also significantly elevated in the prebiotic-treated group (1.21 6 0.06 of control; P , 0.05) (Fig. 4D) . To determine the impact of increased GLP-1 on insulin secretion, plasma was assayed for insulin during the OGTT. At day 28, baseline insulin levels were similar, but during the OGTT the chondroitin sulfate group had a significantly greater insulin response (P , 0.001 for overall treatment effect in two-way ANOVA) (Fig. 4E) . AUC was also markedly increased in the treatment group (14.1 6 0.85 vs 6.96 6 0.23; P , 0.001) (Fig. 4F) . Finally, although differences in weight gain between groups were not observed during this study (day 0 body mass, 22.8 g control and 22.4 g treatment; day 28 body mass, 26.1 g control and 27.1 g treatment), after day 18 a significant reduction in food consumption (AUC day 18 to 28) began to emerge in the treatment group (0.87 6 0.06-fold; P , 0.05) (Fig. 4G and 4H ).
Discussion
The incretin hormone GLP-1 has become an important therapeutic target in the treatment of T2DM and obesity, and strategies to increase GLP-1 remain a major research focus. In addition, the GI microbiome has recently emerged as a potential player in the regulation of metabolic health in part through the production of microbial metabolites. These metabolites include H 2 S, which is an established regulatory gas (gasotransmitter) in several organ systems. Because H 2 S is known to regulate metabolic hormones and H 2 S-producing SRB reside in the same environment of the GLP-1 secreting L-cells, we aimed to determine if H 2 S plays a regulatory role in GLP-1 secretion and its downstream metabolism. Our results indicate that H 2 S directly stimulates GLP-1 secretion and that increasing SRB in mice using a prebiotic diet led to enhanced GLP-1 secretion, enhanced insulin secretion, improved glucose tolerance, and reduced feeding.
When examining the direct effect of a secretagogue on GLP-1 secretion, it is important to demonstrate the effect using a treatment concentration within the physiological range. In our in vitro study, H 2 S donors were used in the mM to mM range. Although these H 2 S donors liberate the gas differently, the concentrations of gas produced over the 2 hours are expected to be within the range of luminal concentrations of H 2 S produced through microbial respiration (19, 21, 35) . This is in contrast to the nM concentrations of H 2 S that are produced endogenously from the colonic epithelium (36) . To estimate the quantity of H 2 S that is present within the colon, mouse colonic content H 2 S was determined. Once again, these concentrations were found to be within the mM range (mmol/g wet weight) and are in line with other work examining fecal H 2 S concentrations (between 0.29 and 1.6 mmol/g) (37-40). We also found that the H 2 S stimulation of GLP-1 secretion occurred through p38 MAPK. This is important because H 2 S is not known to have a cell-based receptor, and the mechanism of H 2 S action remains an active area of research. However, our finding that p38 MAPK is mechanistically involved is in agreement with other studies that have examined the mechanism of H 2 S action in other systems (41) (42) (43) . Importantly, Reimer et al. (44) have demonstrated a role for p38 MAPK phosphorylation in the secretion of GLP-1. Only one chemical inhibitor was tested in this study, and future work should include cell knockdown and in vivo inhibition of p38 MAPK to fully elucidate its role in H 2 Smediated GLP-1 secretion. Nevertheless, this study and others support a role for H 2 S-mediated activation of p38 MAPK as the mechanism for enhanced GLP-1 secretion.
Our finding that H 2 S stimulates GLP-1 secretion appears to contradict a recent study by Bala et al. (45) , who demonstrated that H 2 S inhibits oleanolic acid-stimulated GLP-1 secretion in the STC-1 cell line. There are, however, several important differences between our cell culture experiments. Mainly, their study uses the secretin tumor cell line STC-1. Although this cell line produces and secretes GLP-1, it is derived from the small intestine (46) and may have alternate regulation compared with the colonic-derived GLUTag. Because SRB require the anaerobic environment of the colon, microbial H 2 S concentrations (in the mM to mM range) would likely not be present in the upper small intestine. Therefore, it is possible that the STC-1 from the small intestine, and the GLUTag cells from the colon, use different pathways and react differently to H 2 S stimuli. To strengthen our findings, we examined the impact of increased H 2 S production on GLP-1 and downstream metabolism.
Supplementing the diet with the sulfated glycosaminoglycan, chondroitin sulfate led to an increase in SRB compared with control. This prebiotic had been previously validated to increase SRB (26) , and, unlike other sulfate molecules that are quickly absorbed by the gut, glycan-bound sulfate (such as chondroitin sulfate) is poorly absorbed in the small intestine (47) and is more likely to liberate the sulfate in the distal GI tract, where it can be used by SRB for H 2 S production. Similar to Rey et al. (26) , we observed an increase in the abundance of D. piger and H 2 S levels in mice on this chondroitin sulfate diet. However, our levels of D. piger community abundance were lower than in the study by Rey et al. (26) . This is likely due to their mice being germ free and inoculated with an eight-species defined microbiome community, including D. piger. Control mice in our study also had an increase in SRB after 4 weeks. This is likely due the diet low in fermentable carbohydrate, which enhances the use host-derived sulfated glycans in the lumen and is known to promote growth in SRB (26) . Nevertheless, supplementing additional sulfate in the treatment group by chondroitin sulfate further enhanced these SRB levels. Only mice treated with chondroitin sulfate had increased levels of H 2 S, which suggests additional sulfur substrates are required to increase H 2 S production.
In agreement with our in vitro work, mice treated with chondroitin sulfate (which exhibited higher levels of colonic H 2 S) had a significant improvement in GLP-1 response. However, this difference was observed only after oral glucose administration and not at the baseline (time 0). What may be happening in the H 2 S-enriched in vivo environment is a "priming" of the L-cell in preparation for subsequent glucose-stimulated GLP-1 secretion. Indeed, endocrine cell priming has been described in other cells, such as b-cells and ghrelin cells (48, 49) . Along with increased GLP-1 secretion, we observed improved insulin secretion, improved glucose tolerance, and reduced food consumption in the chondroitin sulfate animals. The latter became apparent in last 9 days of the study, indicating that there was no initial taste aversion to the chondroitin sulfate. These findings are in agreement with GLP-1's established role in mediating increased insulin stimulation and satiety (50) . Surprisingly, we did not observe a significant weight difference during the course of this study. However, this may be due to the short duration of this study (4 weeks). Future studies may examine long-term weight changes in older animals or weight loss interventions to fully elucidate the role of H 2 S in body weight regulation. In addition, future use of germ-free mice given a SRB probiotic and including a wash-out period would strengthen the relationship between microbial H 2 S production and enhanced GLP-1 secretion.
In summary, we have demonstrated a role for H 2 S in the stimulation of GLP-1 secretion. This effect was shown directly in L-cells and indirectly through prebiotic enhancement of the SRB microbiome. These results provide evidence of how microbial gases influence the gut endocrine system and downstream metabolism.
